한빛사논문
- 조회276
Chan-Young Jung,* Hyung Woo Kim,* Sang Hoon Ahn,*,‡,§ Seung Up Kim,*,‡,§ andBeom Seok Kim*
*Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea; ‡Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Republic of Korea; and §Yonsei Liver Center, Severance Hospital, Seoul, Republic of Korea
Corresponding authors : Correspondence to Seung Up Kim or Beom Seok Kim.
Abstract
Of the antiviral agents currently available to patients with chronic hepatitis B (CHB), entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are 2 of 3 first-line agents.1-3 Given the well-known renal and bone toxicity associated with TDF,4 major international hepatitis B virus treatment guidelines recommend ETV over TDF in patients with predisposing factors to kidney function decline.1-3 However, as evidenced by recent studies, nephrotoxicity of antiviral agents is still an issue under debate.5-7 Therefore, we investigated the differences in the risk of kidney function decline in patients with treatment-naive CHB who were treated with ETV or TDF.
논문정보
- Research article
- 2022년 04월 (BRIC 등록일 2022-12-19)
- 국내 연구진
- 의약학 > 응용의학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
